Cargando…

Ventilator associated pneumonia and infection control

Ventilator associated pneumonia (VAP) is the leading cause of morbidity and mortality in intensive care units. The incidence of VAP varies from 7% to 70% in different studies and the mortality rates are 20–75% according to the study population. Aspiration of colonized pathogenic microorganisms on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Alp, Emine, Voss, Andreas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1540438/
https://www.ncbi.nlm.nih.gov/pubmed/16600048
http://dx.doi.org/10.1186/1476-0711-5-7
_version_ 1782129172060045312
author Alp, Emine
Voss, Andreas
author_facet Alp, Emine
Voss, Andreas
author_sort Alp, Emine
collection PubMed
description Ventilator associated pneumonia (VAP) is the leading cause of morbidity and mortality in intensive care units. The incidence of VAP varies from 7% to 70% in different studies and the mortality rates are 20–75% according to the study population. Aspiration of colonized pathogenic microorganisms on the oropharynx and gastrointestinal tract is the main route for the development of VAP. On the other hand, the major risk factor for VAP is intubation and the duration of mechanical ventilation. Diagnosis remains difficult, and studies showed the importance of early initiation of appropriate antibiotic for prognosis. VAP causes extra length of stay in hospital and intensive care units and increases hospital cost. Consequently, infection control policies are more rational and will save money.
format Text
id pubmed-1540438
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15404382006-08-12 Ventilator associated pneumonia and infection control Alp, Emine Voss, Andreas Ann Clin Microbiol Antimicrob Review Ventilator associated pneumonia (VAP) is the leading cause of morbidity and mortality in intensive care units. The incidence of VAP varies from 7% to 70% in different studies and the mortality rates are 20–75% according to the study population. Aspiration of colonized pathogenic microorganisms on the oropharynx and gastrointestinal tract is the main route for the development of VAP. On the other hand, the major risk factor for VAP is intubation and the duration of mechanical ventilation. Diagnosis remains difficult, and studies showed the importance of early initiation of appropriate antibiotic for prognosis. VAP causes extra length of stay in hospital and intensive care units and increases hospital cost. Consequently, infection control policies are more rational and will save money. BioMed Central 2006-04-06 /pmc/articles/PMC1540438/ /pubmed/16600048 http://dx.doi.org/10.1186/1476-0711-5-7 Text en Copyright © 2006 Alp and Voss; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Alp, Emine
Voss, Andreas
Ventilator associated pneumonia and infection control
title Ventilator associated pneumonia and infection control
title_full Ventilator associated pneumonia and infection control
title_fullStr Ventilator associated pneumonia and infection control
title_full_unstemmed Ventilator associated pneumonia and infection control
title_short Ventilator associated pneumonia and infection control
title_sort ventilator associated pneumonia and infection control
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1540438/
https://www.ncbi.nlm.nih.gov/pubmed/16600048
http://dx.doi.org/10.1186/1476-0711-5-7
work_keys_str_mv AT alpemine ventilatorassociatedpneumoniaandinfectioncontrol
AT vossandreas ventilatorassociatedpneumoniaandinfectioncontrol